Author

Rebecca Zhang-Roper

Observed name: Rebecca Yanhui Zhang-Roper

Observed institutions: Siriraj Hospital, GlaxoSmithKline (United Kingdom), Mahidol University, GlaxoSmithKline (United States), GlaxoSmithKline Research & Development Limited (United Kingdom)

OpenAlex ID: A5089973823

Pharmacokinetics, Safety and Efficacy of Maraviroc in Treatment-experienced Pediatric Patients Infected With CCR5-Tropic HIV-1

2017 · Carlo Giaquinto, Muthuhadini Patience Mawela, et al. · The Pediatric Infectious Disease Journal · 12

Hepatic Safety of Maraviroc in Patients with HIV-1 and Hepatitis C and/or B Virus: 144-Week Results from a Randomized, Placebo-Controlled Trial

2016 · Juergen K Rockstroh, Frank Plonski, et al. · Antiviral Therapy · 9

Interim Results of the US Fenfluramine Oral Solution Cardiovascular Safety Registry Study (S12.002)

2025 · Almasa Bass, Diego Morita, et al. · Neurology · 1

Safety, Tolerability, Pharmacokinetics, and Efficacy of Fenfluramine in Combination With Cannabidiol: Results From a Phase 1 Study (P9-9.010)

2025 · Rebecca Zhang-Roper, Aravind Mittur, et al. · Neurology · 1

Understanding the Incidence, Prevalence, Characteristics, and Healthcare Resource Utilization for Patients With Dravet and Lennox-Gastaut Syndromes (P8-11.003)

2025 · Rejena Ameen, Joseph Sullivan, et al. · Neurology

A Retrospective Claims Study Evaluating Mortality in Patients With Lennox-Gastaut or Dravet Syndromes in the United States (P8-11.004)

2025 · Rejena Ameen, Elaine Wirrell, et al. · Neurology

Safety and Effectiveness of Fenfluramine for the Treatment of Seizures in Lennox-Gastaut Syndrome: Results From the Final Analysis of an Open-Label Extension Study (P8-9.002)

2025 · Kelly Knupp, Ingrid Scheffer, et al. · Neurology

A phase 1 study of single and repeat oral doses of GSK3439171A, a highly selective H-PGDS inhibitor, in healthy adult participants

2021 · Thomas Haws, Nilay Thakkar, et al.

Works count: 8

Citation count: 23

H-index: 2

I10-index: 1